IN8bio (Nasdaq: INAB) reported that its Board Compensation Committee granted one new employee a nonqualified stock option to purchase an aggregate of 4,000 shares of common stock under the company’s 2026 Inducement Plan, effective August 3, 2026, as an inducement award under Nasdaq Listing Rule 5635(c)(4).
The option vests over four years: 25% on the employee’s first work anniversary and the remaining 75% in 36 equal monthly installments, subject to continued employment. IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager product candidates, including INB-600, INB-100, and INB-200/400.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The prior -1.28% reaction to a γδ T-cell publication shows the platform record added mixed context t...
Analysis
The prior -1.28% reaction to a γδ T-cell publication shows the platform record added mixed context to company news. The active S-3/A shelf is a financing risk; watch future filings for capital actions and additional program updates.
Key Figures
Option shares:4,000 sharesGrant date:August 3, 2026Vesting period:four years+2 more
5 metrics
Option shares4,000 sharesInducement grant to one employee
Grant dateAugust 3, 20262026 Inducement Plan
Vesting periodfour yearsSubject to continued employment
First vesting tranche25%On the first anniversary of the employee's start date
Remaining installments36 equal monthly installmentsAfter the first anniversary vesting
Company scheduled clinical presentations and an R&D Day across May and June
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Prior news reactions were mixed, with positive clinical data diverging negatively once while other publication and earnings events showed both alignment and divergence.
Key Terms
nonqualified stock option, inducement plan, nasdaq listing rule 5635(c)(4), t cell engagers, +1 more
5 terms
nonqualified stock optionfinancial
"granted one employee a nonqualified stock option to purchase an aggregate of 4,000 shares"
A nonqualified stock option (NQSO) is a company grant that gives an individual the right to buy shares at a set price but does not meet special tax rules for incentive stock options; when exercised the difference between the market price and the exercise price is treated as ordinary income for the recipient and as a tax-deductible expense for the company. It matters to investors because NQSOs affect an employee’s after-tax proceeds, the company’s reported expenses, and potential share dilution—think of it like a cash bonus that converts into stock but is taxed as regular pay when you take it.
inducement planfinancial
"granted pursuant to the Company’s 2026 Inducement Plan"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
t cell engagersmedical
"developing innovative gamma-delta (γδ) T cell therapies and T cell engagers"
T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.
γδ t cellsmedical
"γδ T cells are a specialized population of T cells"
A small subset of T lymphocytes that carry a distinct gamma-delta (γδ) T-cell receptor and act as a rapid-response link between the body’s immediate, non-specific defenses and its slower, targeted immune response. Like a neighborhood watch that can both spot unusual activity and call in specialists, they can quickly recognize stressed, infected, or tumor cells and influence inflammation and immune memory, making them a target or biomarker in drug development, clinical trials, and regulatory assessments that affect biotech valuation.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 4,000 shares of its common stock.The award was approved by the Compensation Committee of the Company’s Board of Directors and was granted pursuant to the Company’s 2026 Inducement Plan, with a grant date of August 3, 2026, as an inducement material to the new employee entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of such employee’s start date, with the remainder of the option vesting in thirty-six (36) equal monthly installments thereafter, subject to continued employment on each vesting date.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.
Investors and Corporate Contact:
IN8bio, Inc. Patrick McCall 646.933.5603 pfmccall@IN8bio.com
Media Contact Kimberly Ha KKH Advisors 917.291.5744 kimberly.ha@kkhadvisors.com
FAQ
What inducement stock option did IN8bio (NASDAQ: INAB) grant on August 3, 2026?
IN8bio granted a nonqualified stock option for 4,000 shares of common stock to one new employee. According to IN8bio, the award was issued under its 2026 Inducement Plan as an inducement material to employment in line with Nasdaq Listing Rule 5635(c)(4).
How does the IN8bio (INAB) inducement stock option vest for the new employee?
The IN8bio inducement stock option vests over four years, starting on the employee’s first anniversary. According to IN8bio, 25% vests at that first anniversary, with the remaining 75% vesting in 36 equal monthly installments, subject to the employee’s continued employment.
Why did IN8bio use Nasdaq Listing Rule 5635(c)(4) for this 4,000-share option grant?
IN8bio used Nasdaq Listing Rule 5635(c)(4) because the option was an inducement material to hiring a new employee. According to IN8bio, this allowed the grant outside shareholder-approved plans under its 2026 Inducement Plan, consistent with Nasdaq requirements.
Does the IN8bio (INAB) inducement grant under the 2026 Inducement Plan dilute existing shareholders?
The option covers 4,000 new shares, which can dilute existing shareholders if exercised. According to IN8bio, the option is a nonqualified stock option granted under the 2026 Inducement Plan specifically as an inducement for a newly hired employee.
What is IN8bio’s clinical pipeline mentioned with the August 2026 inducement grant?
IN8bio highlights a γδ T cell and γδ T cell engager pipeline anchored by INB-600. According to IN8bio, it is also advancing INB-100 for high-risk leukemias and INB-200/400 for newly diagnosed glioblastoma, targeting oncology and autoimmune indications.
What type of employee was eligible for the IN8bio inducement option grant reported in August 2026?
The inducement grant was made to a single new employee joining IN8bio. According to IN8bio, the option was expressly granted as an inducement material to that person entering into employment, consistent with Nasdaq Listing Rule 5635(c)(4) requirements.
